Corsicana & Co. Sells 357 Shares of Pfizer Inc. (NYSE:PFE)

Corsicana & Co. lowered its stake in Pfizer Inc. (NYSE:PFEGet Rating) by 7.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,315 shares of the biopharmaceutical company’s stock after selling 357 shares during the period. Corsicana & Co.’s holdings in Pfizer were worth $226,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of PFE. Worth Asset Management LLC acquired a new stake in Pfizer in the first quarter valued at about $29,000. Rinkey Investments acquired a new stake in Pfizer in the fourth quarter valued at about $32,000. Stuart Chaussee & Associates Inc. boosted its stake in Pfizer by 108.3% in the first quarter. Stuart Chaussee & Associates Inc. now owns 625 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 325 shares in the last quarter. Advanced Research Investment Solutions LLC boosted its stake in Pfizer by 339.3% in the first quarter. Advanced Research Investment Solutions LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 509 shares in the last quarter. Finally, Bivin & Associates Inc. acquired a new stake in Pfizer in the fourth quarter valued at about $37,000. Institutional investors own 67.90% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on PFE. The Goldman Sachs Group set a $50.00 price objective on Pfizer in a research note on Thursday, September 1st. Berenberg Bank set a $44.00 price target on Pfizer in a research note on Wednesday, September 14th. SVB Leerink cut their price target on Pfizer from $55.00 to $53.00 and set a “market perform” rating on the stock in a research note on Friday, July 29th. Morgan Stanley cut their price target on Pfizer from $52.00 to $49.00 and set an “equal weight” rating on the stock in a research note on Friday, July 8th. Finally, JPMorgan Chase & Co. set a $57.00 price target on Pfizer in a research note on Tuesday, June 28th. Nine investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $57.00.

Pfizer Trading Up 1.5 %

Shares of PFE stock opened at $44.57 on Friday. The company has a market cap of $250.14 billion, a P/E ratio of 8.72, a PEG ratio of 0.54 and a beta of 0.70. The stock has a 50 day simple moving average of $48.40 and a two-hundred day simple moving average of $50.33. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.20 and a current ratio of 1.42. Pfizer Inc. has a fifty-two week low of $40.94 and a fifty-two week high of $61.71.

Pfizer (NYSE:PFEGet Rating) last issued its earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.95 by $0.09. The business had revenue of $27.74 billion during the quarter, compared to the consensus estimate of $26.20 billion. Pfizer had a return on equity of 43.18% and a net margin of 28.92%. The firm’s revenue for the quarter was up 46.8% on a year-over-year basis. During the same period in the previous year, the company posted $1.07 earnings per share. Research analysts forecast that Pfizer Inc. will post 6.54 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 5th. Shareholders of record on Friday, November 4th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 3.59%. Pfizer’s payout ratio is currently 31.31%.

Pfizer Profile

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Featured Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.